Clinical trials are the gold standard for testing the safety and efficacy of a treatment or drug, and a keystone in modern medicine. But their grinding timelines and skyrocketing price tags are hindering development and, ultimately, costing lives.
Natasha Loder, The Economist’s health editor, asks Sir Martin Landray, the boss of Protas, a clinical-trial organisation, what can be learned from his pioneering RECOVERY covid-19 trial. Euan Ashley, a cardiologist at Stanford University, explains how to use wearable technology to conduct wholly digital clinical trials. Plus, Alejandro Frangi of the University of Leeds says virtual clinical trials that use computers to model medical interventions can save time and money. Alok Jha, The Economist's science and technology editor, hosts.
We would love to hear from you. Please fill out our listener survey at economist.com/babbagesurvey.
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.
Hosted on Acast. See acast.com/privacy for more information.